Genetically adjusted PSA levels for prostate cancer screening
收藏数据链接：
官方服务：
资源简介：
Prostate-specific antigen (PSA) screening for prostate cancer remains controversial because it increases overdiagnosis and overtreatment of clinically insignificant tumors. Accounting for genetic determinants of constitutive, non-cancer PSA variation has potential to improve screening utility. We discovered 128 genome-wide significant associations (<em>P</em><5×10<sup>-8</sup>) in a multi-ancestry GWAS meta-analysis of 95,768 men and developed a PSA polygenic score (PGS<sub>PSA</sub>) that explains 9.61% of constitutive PSA variation. Here we provide full GWAS summary statistics for the multi-ancestry meta-analysis and ancestry-stratified summary statistics for ~1.2 million variants used to derive a genome-wide PGS<sub>PSA.</sub>
提供机构：
Zenodo创建时间：
2023-02-16
